Clayton Buck

Title: Clayton Buck: Innovator in Lymphocyte Treatment

Introduction

Clayton Buck is a notable inventor based in Berwyn, PA (US), recognized for his contributions to medical treatments targeting activated lymphocytes. With a total of 2 patents, his work focuses on innovative compositions and methods for treating diseases associated with these immune cells.

Latest Patents

Clayton Buck's latest patents include significant advancements in the treatment of diseases related to activated lymphocytes. The first patent, titled "Compositions for treatment of diseases related to activated lymphocytes," details methods for inhibiting proliferation and inducing apoptosis in activated T cells and B cells. This invention also explores the use of 5-HT receptor antagonists for treating diseases associated with these immune cells. The second patent, "Methods for treatment of diseases related to activated lymphocytes," reiterates similar themes, emphasizing the importance of controlling lymphocyte activity in therapeutic contexts.

Career Highlights

Clayton Buck is currently associated with Immune Control Inc., where he applies his expertise in immunology to develop groundbreaking treatments. His work has the potential to significantly impact the field of immunotherapy and disease management.

Collaborations

Clayton collaborates with esteemed colleagues, including Stephen A Roth and Christopher Self, who contribute to the innovative environment at Immune Control Inc. Their combined efforts aim to advance the understanding and treatment of diseases linked to activated lymphocytes.

Conclusion

Clayton Buck's innovative work in the field of lymphocyte treatment showcases his commitment to advancing medical science. His patents reflect a deep understanding of immunology and a dedication to improving patient outcomes through targeted therapies.